Pfizer Inc. PFE
NYSE · Healthcare · Drug Manufacturers - General
$27.40
Close on Fri, 20 Nov 2026 · market value $156B
What the price is betting on
Below its recordAt $27, the price assumes revenue shrinks about 9.2% a year for five years, from $63.6B to about $42.1B by FY2030. That is about the same as what analysts expect for the next two years and less than the company's own last three years.
Revenue growth a year. The price figure comes from a reverse DCF at a 6.7% discount rate.
Track it and Parra checks each report against the path, and tells you when revenue falls behind it.
Own more than PFE? Check up to 5 of your stocks at once, free, no account.
Both sides
Three stories, three values
Bear
$26
Base
$35
Bull
$42
Today $27
- Bear $26. Cash flow falls at least as fast as the share price already implies, because patent losses and pipeline gaps are not replaced and the main drug business keeps shrinking. Revenue has already fallen sharply since its peak and free cash flow slipped again last year. A dividend that earnings do not cover, heavy debt and thin cash leave little room to respond, and the new licensing deal has no sized revenue to offset it.
- Base $35. Cash flow keeps shrinking at about the pace analysts expect as patent losses and a thinner product line weigh on sales. Licensed and acquired medicines offset only part of the loss, and margins stay well above peers, so the latest twelve-month free cash flow is a fair starting point.
- Bull $42. The fall in cash flow flattens sooner than expected. The drug business was already close to flat in the latest quarter, and licensed and acquired medicines such as the new CAR-T deal replace lost sales while margins stay well above peers. Free cash flow then holds near the latest twelve-month level and debt eases. This needs new revenue that the facts do not size, so it is the least likely story.
AI-written stories, valued by code from the same model.
Checkpoints
The revenue the price needs
- YearNeedsAnalysts expect
- FY2026$62B$63.2B, on the path
- FY2027$56.3B$60.7B, on the path
- FY2028$51.1B$55.2B, on the path
- FY2029$46.4B$53.7B, on the path
- FY2030$42.1B$54.3B, on the path
Each year's revenue at −9.2% growth from $63.6B in the 12 months to September 2026.
At a glance
Healthcare · Drug Manufacturers - General · listed on NYSE
- Revenue, FY2025
- $62.6B
- Growth, 3 years a year
- 2.4%
- Cash margin
- 15%
- Net debt
- $53.8B
- Shares, 3-year change
- −0.8%
- Dividend yield
- 6.3%
What other healthcare prices are betting on
Figures from company filings and end-of-day market data, as of the close on Fri, 20 Nov 2026; updated every trading day. This page shows what today's price assumes, not whether to buy or sell. Not investment advice.